Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfisoxazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 12/20 | 0.79 |
| ▸ | EDNRB | P24530 | 9/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfisoxazole SCHEMBL887764 | 1.00 | EDNRA (0.79) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL3221114 | 0.90 | EDNRA (0.82) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL23467 | 0.89 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL788644 | 0.89 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL5917298 | 0.87 | EDNRA (0.97) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL2200933 | 0.87 | EDNRA (0.97) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL5959142 | 0.85 | EDNRA (0.92) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL16097888 | 0.84 | EDNRA (0.89) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL20770061 | 0.82 | EDNRA (0.81) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL28264710 | 0.82 | EDNRA (0.81) | EDNRAEDNRBMEN1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344506-B2 | Rapidly disintegrating oral dissolvable film | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2022-05-31 | — | — | US | claimed |
| US-20170002329-A1 | GENERATING CARDIAC PROGENITOR CELLS FROM PLURIPOTENT STEM CELLS USING ISOXAZOLE OR ISOXAZOLE LIKE COMPOUNDS | IPS HEART | 2017-01-05 | — | — | US | claimed |
| US-20160151453-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3024476-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-06-01 | — | — | EP | claimed |
| WO-2015011254-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-01-29 | — | — | WO | claimed |
| US-20100016333-A1 | Once-a-day (RNA-Polymerase Inhibiting or phenazine) - dihydropteroate synthase inhibiting - dihydrofolate reductase inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by Methicillin-Resistant Staphylococcus aureus | SHIONOGI INC. | 2010-01-21 | — | — | US | claimed |
| WO-2008021089-A2 | ONCE-A-DAY (RNA-POLYMERASE INHIBITING OR PHENAZINE)-DIHYDROPTEROATE SYNTHASE INHIBITING-DIHYDROFOLATE REDUCTASE INHIBITING ANTIBIOTIC PHARMACEUTICAL PRODUCT, FORMULATION THEREOF, AND USE THEREOF IN TREATING INFECTION CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | MIDDLEBROOK PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2002005850-A2 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | claimed |
| US-5357636-A | Flexible protective medical gloves and methods for their use | DRESDNER JR KARL P (US) | 1994-10-25 | — | — | US | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-4853224-A | INTRODUCING DRUG-CONTAINING POLYMERIC MICROCAPSULES INTO INTERIORS OF EYE; SUSTAINED RELEASE | VISIONEX (US) | 1989-08-01 | — | — | US | disclosed |
| EP-0212875-A2 | Medicinal composition and method of making same | Tucker, William Gough (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4344431-A | DISPERSION OF CRYSTALLINE POLYETHYLENE AND ANTAGONIST; INSERTION INTO THE BODY-TIME-RELEASE AGENTS | UNIVERSITY OF DELAWARE (US) | 1982-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002329-A1 | GENERATING CARDIAC PROGENITOR CELLS FROM PLURIPOTENT STEM CELLS USING ISOXAZOLE OR ISOXAZOLE LIKE COMPOUNDS | MYLK2, TNNI3, MYH2 | EDNRA 3628/4885EDNRB 3227/4885MEN1 4864/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | EDNRA 3440/4885EDNRB 4034/4885MEN1 4294/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | EDNRA 319/4885EDNRB 110/4885MEN1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.